Candel Therapeutics
Yahoo Finance • 12 months ago
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
Decreases workforce by approximately 50% and reduces commercial manufacturing expenses to prioritize spend towards topline clinical data readouts for CAN-2409 in non-small cell lung cancer, pancreatic cancer, and prostate cancer in 2024 Pr... Full story
Yahoo Finance • last year
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Initial survival data from phase 2 clinical trial of CAN-2409 in advanced non-small cell lung cancer (NSCLC) showed survival supportive of an increased tail on the maturing survival curveInitial data from phase 2 clinical trial of CAN-2409... Full story
Yahoo Finance • last year
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune surveillance Application of the enLIGHTEN™ Advanced Analytics suite to datas... Full story
Yahoo Finance • last year
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Initial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC) after experimental treatment with CAN-2409 Estimated overall survival rate was 71.4% at 36 months i... Full story
Yahoo Finance • last year
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
CAN-3110 is a first-in-class herpes simplex virus-1 oncolytic immunotherapy candidate with dual activity for oncolysis and immune activation in a single therapeuticIn a first-in-human clinical trial of CAN-3110 in recurrent high-grade glio... Full story
Yahoo Finance • last year
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical trial of CAN-2409 plus standard of care chemoradiation in pancreatic cancerTwo preclinical po... Full story
Yahoo Finance • last year
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
Initial data suggests 12-month survival is consistent with an increased tail on the maturing survival curveNegative or low PD-L1 status appears to be associated with long survival in CAN-2409 treated patientsBiomarker data suggests associa... Full story
Yahoo Finance • last year
Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
NEEDHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, to... Full story
Yahoo Finance • last year
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
Based on forthcoming completion of patient enrollment and duration of follow-up in Cohort 2 from the phase 2 trial in late-stage NSCLC NEEDHAM, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (... Full story
Yahoo Finance • 2 years ago
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patient... Full story
Yahoo Finance • 2 years ago
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
NEEDHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today an... Full story
Yahoo Finance • 2 years ago
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
NEEDHAM, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patie... Full story
Yahoo Finance • 2 years ago
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
Expects to announce clinical trial data from multiple oncology programs in the second half of 2023Extends cash runway into second quarter of 2024 NEEDHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or... Full story
Yahoo Finance • 2 years ago
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
NEEDHAM, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, Preside... Full story
Yahoo Finance • 2 years ago
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
NEEDHAM, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, Preside... Full story
Yahoo Finance • 2 years ago
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer
Updated data from the phase 2 clinical trial of CAN-2409 in non-small cell lung cancer showing disease control rate of 77 percent in patients entering the study with progressive disease, translating into preliminary evidence of improved pr... Full story
Yahoo Finance • 2 years ago
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 agents in patients with late-stage non-small cell lung cancer. Recent clinical data for CAN-3110 and CAN-2409 in high-gra... Full story
Yahoo Finance • 2 years ago
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
CAN-3110 designed to limit replication and promote anti-tumor response to tumor cells while protecting healthy tissueNo dose-limiting toxicities observed in 41 patients with recurrent high-grade glioma (rHGG)Median overall survival was 11.... Full story
Yahoo Finance • 2 years ago
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma
Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standard of careSystemic immune activation was observed in peripheral blood following administr... Full story
Yahoo Finance • 2 years ago
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Discovery collaboration underway with Center for Cellular Immunotherapies Lab at University of Pennsylvania to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy Candidates in Solid Tumor Models Upcoming clinical data p... Full story
